drugset
drugset / Trial / NCT07205198

A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.

NCT07205198 ↗

Phase 1 Recruiting 160 enrolled Shanghai Institute Of Biological Products
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability of SIBP-A10 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).

Timeline

Start
2025-10-31
Primary completion
2028-12-30
Completion
2028-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SIBP-A10 Unknown 0.5 mg/kg Intravenous
Subject SIBP-A10 Unknown 1.5 mg/kg Intravenous
Subject SIBP-A10 Unknown 3 mg/kg Intravenous
Subject SIBP-A10 Unknown 5 mg/kg Intravenous
Subject SIBP-A10 Unknown 7 mg/kg Intravenous
Subject SIBP-A10 Unknown 10 mg/kg Intravenous
Subject SIBP-A10 Unknown 15 mg/kg Intravenous

Indications

metastatic neoplasm